Table 3.
List of phase III clinical trials investigating ADC combination therapies in HER2-positive advanced breast cancer, as of 22 October 2022
| CT full name | CT name | CT code | Setting | ADC | Combo |
|---|---|---|---|---|---|
| A Study of T-DM1 in Combination With Atezolizumab or Placebo as a Treatment for Participants With HER2+ and PD-L1+ Locally Advanced or metastatic BC | KATE3 | NCT04740918 | HER2+ | T-DM1 | Atezolizumab/placebo |
| A Study of Tucatinib versus Placebo in Combination With T-DM1 for Patients With Advanced or Metastatic HER2+ BC | HER2CLIMB 02 | NCT03975647 | HER2+ | T-DM1 | Tucatinib/placebo |
| T-DXd With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2+ Metastatic BC | DESTINY-Breast09 | NCT04784715 | HER2+ | T-DXd | Pertuzumab/placebo |
ADC, antibody–drug conjugate; BC, breast cancer; CT, clinical trial; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1; T-DM1, ado-trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
Source: clinicatrials.gov.